The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis - Wikidata - awgldk - TriplyDB

The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis

The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis

http://www.wikidata.org/entity/Q24633734

about

Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis Advances in Development of New Treatment for Leishmaniasis A screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward?Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotes Trypanothione reductase: a target protein for a combined in vitro and in silico screening approach Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania An open source pharma roadmap The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease Genetic dissection of drug resistance in trypanosomes An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugs Evaluating aziridinyl nitrobenzamide compounds as leishmanicidal prodrugs Antiparasitic chemotherapy: from genomes to mechanisms.Surface-engineered dendrimeric nanoconjugates for macrophage-targeted delivery of amphotericin B: formulation development and in vitro and in vivo evaluation.SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines.Targeting the parasite's DNA with methyltriazenyl purine analogs is a safe, selective, and efficacious antitrypanosomal strategy The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis Evaluation of trypanocidal drugs used for human African trypanosomosis against Trypanosoma lewisi Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.Investigational drugs for visceral leishmaniasis.Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei.New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape.Evaluating 5-Nitrothiazoles as Trypanocidal Agents.Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art.Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells.Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation.Ammonium trichloro [1,2-ethanediolato-O,O']-tellurate cures experimental visceral leishmaniasis by redox modulation of Leishmania donovani trypanothione reductase and inhibiting host integrin linked PI3K/Akt pathway.Nanostructured delivery systems with improved leishmanicidal activity: a critical review.Novel arylalkylamine compounds exhibits potent selective antiparasitic activity against Leishmania major.Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach.Stoking the drug target pipeline for human African trypanosomiasis.Screening a Natural Product-Based Library against Kinetoplastid Parasites.In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series.Innovation in neglected tropical disease drug discovery and development.A role for trypanosomatid aldo-keto reductases in methylglyoxal, prostaglandin and isoprostane metabolism Antitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals

P2860

Q26863285-ED37CE23-05F8-4CF4-B735-1662AABD07E2 Q27011766-7DE8AB7B-607E-4410-A04B-5F0B9CBE4318 Q28082097-ADDBA2D6-FE2D-4D3A-94BB-31DBEDDE572C Q28541690-4F722329-9784-45B5-9D6F-9F23FBC6B43F Q28542767-CF00ABFD-0840-4559-8C0F-443A7EBD2172 Q28547882-AB5EF361-5E21-48D0-B174-9477A3F36EA2 Q28553178-3F882524-FEDE-4CA8-ABD0-91510C59891F Q29475096-2578BCAF-001C-4935-BF30-E856C94719B8 Q30447200-F6042F57-C438-4DBA-A1E4-74EA5DECECB1 Q33681753-EA6EECB7-3C6B-4B5D-AF2D-278654A59BB8 Q34058185-1B0B70BE-C630-40BE-B181-CE43B0358BB6 Q34647009-04036CA7-3893-4F7C-8EE1-3B2E4CB1E642 Q34942136-C233923D-BE44-47B9-8A17-353C608EB44F Q35027309-E0CEFB19-8899-49B5-9786-1790495728FA Q35238319-6B95927A-BF94-4743-A34A-814549E0D43B Q35385158-3C11592C-8844-4AF5-965F-4DC7EFEECB9E Q35952211-72E0A970-830A-440A-8C7F-89F899401605 Q36158447-B51E5CE4-AC44-4287-9463-D47B61D61320 Q36932080-55DEA143-220E-453E-B073-7E26F793D7F9 Q37242110-D9C407D2-56E3-4ADB-9E26-534804F8EAE9 Q37377483-AAC2A86F-A9AE-4FB3-B3F6-3C7AEF109F7E Q38269581-1DB68D8D-5082-40F1-8576-6A55EF44BE3E Q38270529-47D7CDA7-69B0-4AFE-9888-C138EE572D14 Q38296306-5BBD149C-4F0B-49EB-9B18-61678E01A20A Q38367643-021FEE30-9CAC-4419-A7D9-4022CE3A8676 Q38939544-25333C26-5BDC-43C9-AC28-ACA205DEAE60 Q39003990-5273E970-82E1-4F39-9880-4BCBF7060A4C Q39144812-F9EBCC15-3AA0-4816-9300-C1582F5F1B1D Q39233120-6AC268BE-A6C3-459F-900F-27418CFFFBCC Q40050000-E00D9C05-7F54-4B5B-BB53-B8E81CB22218 Q40099567-057B6088-2310-4FEC-A20F-BDCD7BAF5974 Q40496908-00A07B48-2A44-44E5-87E9-A65C86912C04 Q41034709-E132B548-90CE-47DE-A511-EBE03130C6E7 Q42703391-6D134C78-6237-4370-951F-4FD362C86837 Q42796077-4ECFC431-2BA0-4D21-BDBD-B9B3661B2DC9 Q50051086-28CE634E-A64F-4010-8DC4-852E4D3F4291 Q55459515-81541D47-8E12-4EA1-8484-CE102D77CF51 Q58694598-423BD715-AA57-481F-8488-3D31AC38D69B Q58850065-54B32D7C-F675-49E4-868F-203597BE2B52

P2860

The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis

http://www.wikidata.org/entity/Q24633734

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The anti-trypanosome drug fexi ...... reating visceral leishmaniasis

@ast

The anti-trypanosome drug fexi ...... reating visceral leishmaniasis

@en

The anti-trypanosome drug fexi ...... reating visceral leishmaniasis

@nl

type

label

The anti-trypanosome drug fexi ...... reating visceral leishmaniasis

@ast

The anti-trypanosome drug fexi ...... reating visceral leishmaniasis

@en

The anti-trypanosome drug fexi ...... reating visceral leishmaniasis

@nl

prefLabel

The anti-trypanosome drug fexi ...... reating visceral leishmaniasis

@ast

The anti-trypanosome drug fexi ...... reating visceral leishmaniasis

@en

The anti-trypanosome drug fexi ...... reating visceral leishmaniasis

@nl

P1433

Q24633734-E64CB94D-B958-4868-B945-7E7C869DFFB3

P1476

Q24633734-08826692-0425-4EAA-BCB7-100B98D1A48A

P2093

Q24633734-21DF4B69-A21F-445A-90D0-579D595484C6

Q24633734-6F13C3D0-63F4-4F18-ABE8-7DB863C83A37

Q24633734-710FAE38-7A1C-4639-870E-63E40D48AEAD

Q24633734-8F64E615-5DE7-443B-BA65-58A313C25C75

Q24633734-B47DE328-C459-448B-9297-04F1EB9CC95B

Q24633734-E018B690-0086-4465-B64C-748D8E320BE1

P2860

Q24633734-094E4E61-BB63-43C0-B998-E4F8D387248A

Q24633734-12209649-1024-417C-B3AD-A054D1F2CFA8

Q24633734-12D69E62-018B-43A0-83AA-D3E954B0BB13

Q24633734-15DB6F95-F381-44D6-9377-C8315C41F674

Q24633734-1EAFC2BB-EAA6-4F20-A150-0739DF86DC3D

Q24633734-204CDC83-4604-472B-A23E-E034E78F64D9

Q24633734-21E9545A-47A2-4026-9A07-D82A17EF7D3E

Q24633734-22E89C2C-315E-49F2-AB81-43608A54895B

Q24633734-22FF1ED4-A147-45A6-BBF0-CC2D6817CDE3

Q24633734-2BDD321B-1ED0-450E-8718-394FF7CF0B20

P304

Q24633734-84764858-B005-498A-A3CF-15F7679E5E12

P31

Q24633734-FFBF4634-5C68-4A33-8709-D8AF39A4630B

P3181

Q24633734-C85B8F75-3B62-4C95-9C68-7ABF6D34E74F

P356

Q24633734-6F4E7944-94ED-4A81-B64A-E9765A531197

P407

Q24633734-282902F5-27B5-4579-95FE-86A2671E42AB

P433

Q24633734-B8316AA7-4EC8-4E36-90D8-00B4028B64BA

P478

Q24633734-71F59131-1216-45F7-B3C6-BCDF6E2D3EFF

P50

Q24633734-93903E47-2884-47D3-8B76-5F846341B80C

Q24633734-BC308894-EACF-4CA7-90D1-44EECB923811

P577

Q24633734-AE7248EF-F7D3-4D8D-A780-AD1689656B5A

P5875

Q24633734-ABF820D1-3E31-46B4-9ED4-1E397CED0BC5

P698

Q24633734-E6045154-1F4C-4575-A956-69F5870FC962

P921

Q24633734-10DB5423-9D15-492B-8A86-9C4040142B34

Q24633734-A86511F0-B38C-48C9-A350-B911225889AD

P932

Q24633734-1FFF90AA-29F8-466B-BDDE-1971B36261A0

P3181

P356

SCITRANSLMED.3003326

P1433

Science Translational Medicine

P1476

The anti-trypanosome drug fexi ...... reating visceral leishmaniasis

@en

P2093

Frederick R C Simeons

http://www.w3.org/2001/XMLSchema#string

Kevin D Read

http://www.w3.org/2001/XMLSchema#string

Laste Stojanovski

http://www.w3.org/2001/XMLSchema#string

Robert Kime

http://www.w3.org/2001/XMLSchema#string

Stephen Patterson

http://www.w3.org/2001/XMLSchema#string

Suzanne Norval

http://www.w3.org/2001/XMLSchema#string

P2860

Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

Developments in the treatment of visceral leishmaniasis

Control of visceral leishmaniasis in latin america-a systematic review

Drug resistance in leishmaniasis

Dose translation from animal to human studies revisited

Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis.

Control of the leishmaniases.

P304

119re1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1413541

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCITRANSLMED.3003326

http://www.w3.org/2001/XMLSchema#string

P407

P433

119

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Alan H Fairlamb

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221802376

http://www.w3.org/2001/XMLSchema#string

P698

22301556

http://www.w3.org/2001/XMLSchema#string

P921

visceral leishmaniasis

P932

3457684

http://www.w3.org/2001/XMLSchema#string